Valuation : Candel Therapeutics, Inc.

Market Cap 1.01B 869M 816M 746M 1.39B 95.48B 1.4B 9.65B 3.76B 48.79B 3.79B 3.71B 157B P/E 2026 *
-9.41x
P/E 2027 * -12.1x
Enterprise Value 1.01B 869M 816M 746M 1.39B 95.48B 1.4B 9.65B 3.76B 48.79B 3.79B 3.71B 157B EV / Sales 2026 *
-
EV / Sales 2027 * 23.3x
Free-Float
85.01%
Yield 2026 *
-
Yield 2027 * -
08-14 BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 MT
08-13 Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Candel Therapeutics Q2 Loss Widens MT
08-13 Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss MT
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-22 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-21 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI

Last Transcript : Candel Therapeutics, Inc.

1 day-1.74%
1 week-2.33%
Current month-0.77%
1 month+29.57%
3 months+54.04%
6 months+153.82%
Current year+129.56%
1 week 12.6
Extreme 12.602
13.8
1 month 10.09
Extreme 10.09
14
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

Chief Technology Officer

-7,000 0.0096%
06/07/26 Free

Executive/Senior Manager

285,000 0.3890%
30/06/26 Free

Director

381 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-2.33%+121.33%+971.90% 1.01B
-0.24%-0.99%+3.26%+18.17% 50.14B
+0.78%-2.12%+433.44%+501.63% 44.85B
+2.95%+3.87%+47.83%+21.08% 43.43B
+0.25%-3.49%+9.23%+73.60% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.43%+8.34% - - 17.56B
+0.06%-4.15%+25.36%+116.96% 16.55B
+0.93%+0.88%+19.64%+29.70% 14.65B
+0.54%-0.59%+81.92%+39.94% 13.93B
Average +0.59%-0.75%+84.09%+202.45% 27.62B
Weighted average by Cap. +0.88%-1.12%+94.80%+127.12%

Financials

2026 *2027 *
Net sales - 43.38M 37.33M 35.03M 32.05M 59.82M 4.1B 60.29M 414M 161M 2.1B 163M 159M 6.75B
Net income -101M -86.98M -81.62M -74.68M -139M -9.56B -140M -966M -376M -4.88B -380M -371M -15.73B -85.65M -73.69M -69.16M -63.27M -118M -8.1B -119M -818M -319M -4.14B -322M -315M -13.33B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
04/09/26 $12.97 -1.74% 626,087
02/09/26 $13.20 +2.72% 807,852
01/09/26 $12.85 -1.68% 935,641
31/08/26 $13.07 0.00% 895,013
28/08/26 $13.07 -4.95% 1,236,463
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.20USD
Average target price
21.00USD
Spread / Average Target
+59.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock